# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Reveals Consumers Paid $21B Out-of-Pocket in 2024, Averaging $16.26 Per Prescription
Morgan Stanley analyst Craig Hettenbach maintains GoodRx Holdings (NASDAQ:GDRX) with a Equal-Weight and raises the price tar...
GoodRx has been upgraded by RBC Capital Markets due to the growth potential from the Integrated Savings Program, direct contrac...
RBC Capital analyst Mark Mahaney upgrades GoodRx Holdings (NASDAQ:GDRX) from Sector Perform to Outperform and raises the pri...
Barclays analyst Stephanie Davis maintains GoodRx Holdings (NASDAQ:GDRX) with a Overweight and raises the price target from ...
Raymond James analyst John Ransom upgrades GoodRx Holdings (NASDAQ:GDRX) from Market Perform to Outperform and announces $10...
TD Cowen analyst Charles Rhyee maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and raises the price target from $14 to $16.